| 1. |
(CBRS07014) (NSABP42)A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer |
| 2. |
U8700: Study for using radiosurgery on limited metastases of breast cancer |
| 3. |
(CBRS08117) N063D: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study: A Randomized, Multi-center, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with Her2/ErbB2 Positive Primary Breast Cancer. |
| 4. |
(CBRS07064) (S0622) Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
|
| 5. |
(IBRS07002) Prospective, randomized, double-blind, stratified, placebo-controlled, multi-center, 3 arm trial of continued efficacy and safety of Zometa® (every 4 weeks vs. every 12 weeks vs. placebo) in patients with documented bone metastases from breast cancer. |
| 6. |
(CBRS06003) (PACCT-1)Program for the Assessment of Clinical Cancer Test (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. |
| 7. |
(CBRS08068) CALGB40503 - Endocrine Therapy in Combination with Anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865: IND 7921) For Women with Hormone Receptor-Positive Advanced Breast Cancer. |
| 8. |
(CBRS08114) S0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. |
| 9. |
(CBRS08071) E5103 - Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer. |
Email this page
